Job Title
Clinical Trials Coordinator
Department
WMS - Warwick Clinical Trials Unit
Email
- Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
- Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
- Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
- Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
- Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
- Poole, C. J., Hiller, Louise, Howard, H. C., Loi, Shrushma, Dunn, Janet A., Canney, P., Wardley, A. M., Crown, J. P., Coleman, R. E., Verrill, M. W., Ellis, P. A., Leonard, R. C., Spooner, David A., Earl, Helena M., 2006. Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 14-17, 2006, Published in BREAST CANCER RESEARCH AND TREATMENT, pp. S114-S114
Title | Funder | Award start | Award end |
---|---|---|---|
Second Recosting for extension of the Persephone HTA Trial | National Institute for Health Research (DoH) | 01 Jul 2013 | 30 Jun 2016 |
3 month extention of the Persephone HTA Trial | National Institute for Health Research (DoH) | 01 Apr 2013 | 30 Jun 2013 |